BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25004339)

  • 41. [Application of high-risk human papillomavirus testing in women with abnormal cytology].
    Ou H; Bian ML; Zhang XY; Chen QY; Li M; Chen Y; Liu J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):608-11. PubMed ID: 18051714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia?
    Adam E; Kaufman RH; Berkova Z; Icenogle J; Reeves WC
    Am J Obstet Gynecol; 1998 Jun; 178(6):1235-44. PubMed ID: 9662307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liquid-based cytology--new possibilities in the diagnosis of cervical lesions.
    Juric D; Mahovlić V; Rajhvajn S; Ovanin-Rakić A; Skopljanac-Macina L; Barisić A; Projić IS; Babić D; Susa M; Corusić A; Oresković S
    Coll Antropol; 2010 Mar; 34(1):19-24. PubMed ID: 20432728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence of cervical high-grade squamous intraepithelial lesions and squamous cell carcinoma in women with high-risk human papillomavirus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype.
    Gu L; Hong Z; Gao H; Qiu L; Di W
    Cytopathology; 2019 Jul; 30(4):419-425. PubMed ID: 31069857
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of human papillomavirus testing in the management of atypical glandular cells.
    Schnatz PF; Sharpless KE; O'Sullivan DM
    J Low Genit Tract Dis; 2009 Apr; 13(2):94-101. PubMed ID: 19387129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
    J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study.
    Wentzensen N; Wilson LE; Wheeler CM; Carreon JD; Gravitt PE; Schiffman M; Castle PE
    Cancer Res; 2010 Nov; 70(21):8578-86. PubMed ID: 20959485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anal and Cervical High-Risk Human Papillomavirus Genotyping in Women With and Without Genital Neoplasia.
    Bregar AJ; Cronin B; Luis C; DiSilvestro P; Schechter S; Pisharodi L; Raker C; Clark M; Robison K
    J Low Genit Tract Dis; 2018 Apr; 22(2):115-119. PubMed ID: 29481422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation of human papilloma virus infection with cytology, colposcopy and histopathological examination of the bioptic tissue in low- and high-grade intraepithelial lesions.
    Jovanović AM; Dikic SD; Jovanovic V; Zamurovic M; Nikolic B; Krsic V; Rakic S; Stanimirovic B
    Eur J Gynaecol Oncol; 2012; 33(5):512-6. PubMed ID: 23185799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human Papillomavirus Detection and Abnormal Anal Cytology in HIV-infected Patients Using p16/Ki-67 Dual-Staining.
    Patarapadungkit N; Khonhan P; Pisuttimarn P; Pientong C; Ekalaksananan T; Koonmee S
    Asian Pac J Cancer Prev; 2020 Jul; 21(7):2013-2019. PubMed ID: 32711427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation.
    Lytwyn A; Sellors JW; Mahony JB; Daya D; Chapman W; Howard M; Roth P; Lorincz AT; Gafni A; Walter SD
    Arch Pathol Lab Med; 2003 Sep; 127(9):1169-75. PubMed ID: 12946228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear.
    Monsonego J; Bohbot JM; Pollini G; Krawec C; Vincent C; Merignargues I; Haroun F; Sednaoui P; Monfort L; Dachez R; Syrjänen K
    Gynecol Oncol; 2005 Oct; 99(1):160-8. PubMed ID: 16023184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes.
    Sherman ME; Castle PE; Solomon D
    Cancer; 2006 Oct; 108(5):298-305. PubMed ID: 16544318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Follow-up by combined cytology and human papillomavirus testing for patients post-cone biopsy: results of a long-term follow-up.
    Bar-Am A; Gamzu R; Levin I; Fainaru O; Niv J; Almog B
    Gynecol Oncol; 2003 Oct; 91(1):149-53. PubMed ID: 14529675
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cervical cytology with a diagnosis of atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H): a follow-up study with corresponding histology and significance of predicting dysplasia by human papillomavirus (HPV) DNA testing.
    Gilani SM; Tashjian R; Fathallah L
    Arch Gynecol Obstet; 2014 Mar; 289(3):645-8. PubMed ID: 24002355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
    Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
    [No Abstract]   [Full Text] [Related]  

  • 60. Experience of Combined Liquid Based Cervical Cytology and High-Risk HPV mRNA for Cervical Cancer Screening in Thammasat University Hospital.
    Muangto T; Chanthasenanont A; Lertvutivivat S; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
    Asian Pac J Cancer Prev; 2016; 17(9):4409-4413. PubMed ID: 27797253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.